In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Nunnally, Natalie S., Etienne, Kizee A., Angulo, David, Lockhart, Shawn R., Berkow, Elizabeth L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2019
Konular:
Susceptibility
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811432/
https://ncbi.nlm.nih.gov/pubmed/31481447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01692-19
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller